Targeted therapeutic strategies for the management of renal cell carcinoma

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 284-290

  Singer, Eric A ^a   Gupta, Gopal N ^b   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chromophobe; clear cell; hereditary leiomyomatosis and renal cell carcinoma; hereditary papillary renal cancer; mammalian target of rapamycin; papillary; renal cell carcinoma; targeted therapy; vascular endothelial growth factor; von Hippel Lindau

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; DOVITINIB; EVEROLIMUS; FORETINIB; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PLACEBO; RAPAMYCIN; RILOTUMUMAB; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ADVANCED CANCER; CANCER GROWTH; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLEAR CELL CARCINOMA; GENE MUTATION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SEQUENCE ANALYSIS; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TYPE 1 PAPILLARY RENAL CELL CARCINOMA; TYPE 2 PAPILLARY RENAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; PYRIDINES; PYRIMIDINES; SULFONAMIDES; TUBEROUS SCLEROSIS; UNITED STATES;

EID: 84859844667     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328351c646     Document Type: Review

References (59)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Siegel R, Ward E, Brawley O, et al. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
3. Howlander N, Noone AM, Krapcho M, et al. Seer cancer statistics review, 1975-2008, national cancer institute. 2011 http://seer.cancer.gov/statfacts/ html/kidrp.html#risk. [Accessed 2 February 2012]
4. Singer EA, Bratslavsky G, Linehan WM, et al. Targeted therapies for nonclear renal cell carcinoma. Target Oncol 2010; 5:119-129.
5. Singer EA, Gupta GN, Srinivasan R. Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol 2011; 23:283-289.
6. NIH. Clinical trials registry. 2012 http://clinicaltrials.gov/ct2/home. [Accessed 2 February 2012]
7. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490. (Pubitemid 41770167)
8. Latif F, Tory K, Gnarra J, et al. Identification of the von hippel-lindau disease tumor suppressor gene. Science 1993; 260:1317-1320. (Pubitemid 23231974)
9. Moore LE, Nickerson ML, Brennan P, et al. Von hippel-lindau (vhl) inactivation in sporadic clear cell renal cancer: associations with germline vhl polymorphisms and etiologic risk factors. PLoS Genet 2011; 7:e1002312.
10. & Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the swi/snf complex gene pbrm1 in renal carcinoma. Nature 2011; 469:539-542.
11. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
12. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
13. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (avoren): final analysis of overall survival. J Clin Oncol 2010; 28:2144-2150.
14. Rini BI, Halabi S, Rosenberg JE, et al. Phase iii trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of calgb 90206. J Clin Oncol 2010; 28:2137-2143.
15. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
16. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-4265.
17. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
18. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
19. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): a randomised phase 3 trial. Lancet 2011; 378:1931-1939.
20. Cella D, Yount S, Du H, et al. Development and validation of the functional assessment of cancer therapy-kidney symptom index (fksi). J Support Oncol 2006; 4:191-199. (Pubitemid 43890980)
21. Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 2007; 10:285-293. (Pubitemid 47077253)
22. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73. (Pubitemid 27198158)
23. Peruzzi B, Bottaro DP. Targeting the c-met signaling pathway in cancer. Clin Cancer Res 2006; 12:3657-3660. (Pubitemid 44000247)
24. Schoffski P, Garcia JA, Stadler WM, et al. A phase II study of the efficacy and safety of amg 102 in patients with metastatic renal cell carcinoma. BJU Int 2011; 108:679-686.
25. Srinivasan R, Choueiri TK, Vaishampayan U. A phase II study of the dual met/vegfr2 inhibitor xl880 in patients (pts) with papillary renal carcinoma (prc). J Clin Oncol 2008; 26:5103.
26. Srinivasan R, Linehan WM, Vaishampayan U. A phase II study of two dosing regimens of gsk 1363089 (gsk089), a dual met/vegfr2 inhibitor, in patients (pts) with papillary renal carcinoma (prc). J Clin Oncol 2009; 27:5103.
27. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26:202-209.
28. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69:230-235. (Pubitemid 46274917)
29. Isaacs JS, Jung YJ, Mole DR, et al. Hif overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of hif stability. Cancer Cell 2005; 8:143-153. (Pubitemid 41132743)
30. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29:4080-4090.
31. Tong WH, Sourbier C, Kovtunovych G, et al. The glycolytic shift in fumaratehydratase-deficient kidney cancer lowers ampk levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011; 20:315-327.
32. NIH. A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (hlrcc) or sporadic papillary renal cell cancer. 2012. http://clinicaltrials.gov/ct2/show/ NCT01130519? term=bevacizumab+and+erlotinib&rank=2. [Accessed 2 February 2012]
33. Eble JN, Sauter G, Epstein JI, et al., editors. World health organization classification of tumours. Pathology and genetics of tumours of the genitourinary system and male genital organs. Lyon, France: IARC Press; 2004.
34. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the aspltfe3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001; 159:179-192. (Pubitemid 33704203)
35. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal hmb45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 2001; 158:2089-2096. (Pubitemid 32545194)
36. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology 2010; 42:369-373.
37. Malouf GG, Camparo P, Molinie V, et al. Transcription factor e3 and transcription factor eb renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol 2011; 185:24-29.
38. Hua X, Liu X, Ansari DO, et al. Synergistic cooperation of tfe3 and smad proteins in tgf-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 1998; 12:3084-3095. (Pubitemid 28469309)
39. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (rcc): extended immunohistochemical profile emphasizing novel rcc markers. Am J Surg Pathol 2010; 34:1295-1303.
40. Tsuda M, Davis IJ, Argani P, et al. Tfe3 fusions activate met signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic met inhibition. Cancer Res 2007; 67:919-929.
41. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factortargeted therapy for the treatment of adult metastatic xp11.2 translocation renal cell carcinoma. Cancer 2010; 116:5219-5225.
42. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic xp11 translocation/tfe3 gene fusion renal cell carcinoma (rcc): a report from the juvenile rcc network. Ann Oncol 2010; 21:1834-1838.
43. Volpe A, Novara G, Antonelli A, et al. Chromophobe renal cell carcinoma (rcc): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 2011. [Epub ahead of print]
44. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994; 145:356-364. (Pubitemid 24245836)
45. Tan MH, Wong CF, Tan HL, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer 2010; 10:196.
46. Pan CC, Chen PC, Chiang H. Overexpression of kit (cd117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 2004; 121:878-883. (Pubitemid 38669283)
47. Pavlovich CP, Grubb RL 3rd, Hurley K, et al. Evaluation and management of renal tumors in the birt-hogg-dube syndrome. J Urol 2005; 173:1482-1486. (Pubitemid 40524753)
48. Schmidt LS, Warren MB, Nickerson ML, et al. Birt-hogg-dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001; 69:876-882. (Pubitemid 32868532)
49. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the birt-hogg-dube syndrome. Cancer Cell 2002; 2:157-164. (Pubitemid 41039116)
50. Baba M, Furihata M, Hong SB, et al. Kidney-targeted birt-hogg-dube gene inactivation in a mouse model: erk1/2 and akt-mtor activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008; 100:140-154. (Pubitemid 351480566)
51. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.
52. Ricketts C, Woodward ER, Killick P, et al. Germline sdhb mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008; 100:1260-1262.
53. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of krebs cycle intermediates and over-expression of hif1alpha in tumours which result from germline fh and sdh mutations. Hum Mol Genet 2005; 14:2231-2239. (Pubitemid 41418022)
54. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657-668.
55. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7:277-285.
56. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355:1345-1356.
57. Bjornsson J, Short MP, Kwiatkowski DJ, et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 1996; 149:1201-1208. (Pubitemid 26337239)
58. Kato I, Inayama Y, Yamanaka S, et al. Epithelioid angiomyolipoma of the kidney. Pathol Int 2009; 59:38-43.
59. Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and vegf-d levels decrease. PLoS One 2011; 6:e23379.